GH RESEARCH PLC (GHRS) Stock Price, Quote, News and Overview
NASDAQ:GHRS - Nasdaq - IE000GID8VI0 - Common Stock - Currency: USD
GHRS Quote, Performance and Key Statistics
GH RESEARCH PLC
NASDAQ:GHRS (2/4/2025, 8:00:01 PM)
Premarket: 16.2 -0.12 (-0.74%)16.32
-1.67 (-9.28%)
The current stock price of GHRS is 16.32 USD. In the past month the price increased by 80.73%. In the past year, price increased by 102.73%.
GHRS Latest News, Press Releases and Analysis
Unusual volume stocks in Tuesday's session
Let's have a look at the stocks with an unusual volume in today's session.
GH Research Announces Pricing of $150 Million Public Offering
GH Research Announces Pricing of $150 Million Public Offering
DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives...
GH Research Announces Proposed Public Offering
GH Research Announces Proposed Public Offering
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the...
GHRS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 81.23 | 784.20B | ||
| JNJ | JOHNSON & JOHNSON | 15.36 | 369.55B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.01 | 366.85B | ||
| MRK | MERCK & CO. INC. | 11.88 | 229.54B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.1 | 213.85B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.32 | 210.86B | ||
| PFE | PFIZER INC | 8.32 | 146.61B | ||
| SNY | SANOFI-ADR | 13.51 | 134.13B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.53 | 119.91B | ||
| ZTS | ZOETIS INC | 29.9 | 77.71B | ||
| GSK | GSK PLC-SPON ADR | 8.42 | 71.08B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.98 | 42.23B |
Related stock screener links
About GHRS
Company Profile
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 49 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The firm's pipeline includes GH001, GH002 and GH003. The firm focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Company Info
GH RESEARCH PLC
Joshua Dawson House, Dawson Street
DUBLIN LEINSTER IE
CEO: Theis Terwey
Employees: 49
Company Website: http://www.ghres.com
Investor Relations: https://investor.ghres.com/
Phone: 35314378334
GHRS FAQ
What is the stock price of GHRS?
The current stock price of GHRS is 16.32 USD.
What is the symbol for GH RESEARCH PLC stock?
The exchange symbol of GH RESEARCH PLC is GHRS and it is listed on the Nasdaq exchange.
On which exchange is GHRS stock listed?
GHRS stock is listed on the Nasdaq exchange.
Is GHRS a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for GHRS, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of GHRS.
Does GHRS stock pay dividends?
GHRS does not pay a dividend.
When does GHRS stock report earnings?
GHRS will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of GHRS?
GHRS does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).
What is the Short Interest ratio of GHRS stock?
The outstanding short interest for GHRS is 7.77% of its float.
GHRS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GHRS. When comparing the yearly performance of all stocks, GHRS is one of the better performing stocks in the market, outperforming 96.8% of all stocks.
GHRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GHRS. The financial health of GHRS is average, but there are quite some concerns on its profitability.
GHRS Financial Highlights
Over the last trailing twelve months GHRS reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by -0.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.83% | ||
| ROE | -18.79% | ||
| Debt/Equity | 0 |
GHRS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to GHRS. The Buy consensus is the average rating of analysts ratings from 11 analysts.